19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Cochlear hearing loss in patients with Laron syndrome.

      European Archives of Oto-Rhino-Laryngology
      Acoustic Impedance Tests, Adolescent, Age Determination by Skeleton, Audiometry, Pure-Tone, Audiometry, Speech, Child, Child, Preschool, Evoked Potentials, Auditory, Brain Stem, drug effects, Female, Hearing Loss, Sensorineural, diagnosis, drug therapy, Humans, Hyperacusis, Infant, Insulin-Like Growth Factor I, therapeutic use, Laron Syndrome, Loudness Perception, Male, Otoacoustic Emissions, Spontaneous, Prospective Studies, Reflex, Acoustic, Secondary Prevention, Young Adult

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The aim of this prospective clinical study was to test auditory function in patients with Laron syndrome, either untreated or treated with insulin-like growth factor I (IGF-I). The study group consisted of 11 patients with Laron syndrome: 5 untreated adults, 5 children and young adults treated with replacement IGF-I starting at bone age <2 years, and 1 adolescent who started replacement therapy at bone age 4.6 years. The auditory evaluation included pure tone and speech audiometry, tympanometry and acoustic reflexes, otoacoustic emissions, loudness dynamics, auditory brain stem responses and a hyperacusis questionnaire. All untreated patients and the patient who started treatment late had various degrees of sensorineural hearing loss and auditory hypersensitivity; acoustic middle ear reflexes were absent in most of them. All treated children had normal hearing and no auditory hypersensitivity; most had recordable middle ear acoustic reflexes. In conclusion, auditory defects seem to be associated with Laron syndrome and may be prevented by starting treatment with IGF-I at an early developmental age.

          Related collections

          Author and article information

          Comments

          Comment on this article